Kardigan

Kardigan

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://www.kardigan.bio

Last Round

Series B

10/14/2025

Total Funding Raised

$554M

Momentum Score

50 /100

Company Overview

Kardigan is a biopharmaceutical company focused on modernizing cardiovascular drug development. Founded in 2023 by former executives of MyoKardia, the company launched in January 2025 with a $300 million Series A financing. Kardigan aims to develop multiple targeted treatments in parallel, moving beyond symptom management to functional cures for cardiovascular diseases. The company's R&D platform utilizes a proprietary set of cardiac-specific tools and a portfolio of late-stage clinical candidates to match disease drivers with treatment responders, aiming to streamline clinical trials. Kardigan has offices in South San Francisco, California, and Princeton, New Jersey.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine, Medical AI

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting, Data as a Service

AI Layer

Application

Keywords

precision cardiologycardiovascular drug developmentpersonalized medicinelate-stage drug candidatesheart disease therapyAI drug discoverydrug development platformbiopharmaceutical companycardiac intelligencereal-world dataRWDAI clinical trialspatient matchingdrug in-licensingcardiomyopathy treatmentpatient monitoring software

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Kardigan Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Kardigan Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series B10/14/2025
Series A1/10/2025

Key People

Founding team and executive leadership

Tassos Gianakakos

Co-founder, Chief Executive Officer And Chair

Founding Team

Brianne J.

Chief Financial Officer

Executive Team

Kardigan Investors

Notable investors and investment history

InvestorRounds
Perceptive AdvisorsSeries A
HRTG PartnersSeries B, Series A
ARCH Venture PartnersSeries B, Series A
Fidelity Management & Research CompanySeries B
ARCH Venture PartnersSeries B, Series A
T. Rowe PriceSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 28, 2026

    Will present danicamtiv data at HFSA Annual Scientific Meeting 2025.

  • Mar 5, 2026

    FDA-cleared Prolaio clinical intelligence platform for cardiology launched.

Kardigan Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Kardigan Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Kardigan's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range167
Year Founded2023
Last Funding10/14/2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







DisclaimerAll investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.